Drug Profile

Matrix Metalloproteinase targeting radiopharmaceutical - Bicycle Therapeutics/German Cancer Research Center (DKFZ)

Latest Information Update: 21 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bicycle Therapeutics
Developer Bicycle Therapeutics; German Cancer Research Center
Class Antineoplastics; Bicyclic peptide drug conjugates; Drug conjugates; Radioisotopes; Radiopharmaceuticals
Mechanism of Action Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Clinical Phase Unknown Cancer

Most Recent Events

08 Aug 2025 Bicycle Therapeutics plans company-sponsored clinical trials in 2026
29 Apr 2025 Clinical trials in Cancer (Parenteral) before April 2025
29 Apr 2025 Pharmacokinetics data from clinical trial in Cancer released by Bicycle Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com